Clinical pharmacology of recombinant human erythropoietin (r-HuEPO)
Affiliations
- PMID: 2345710
Item in Clipboard
Clinical pharmacology of recombinant human erythropoietin (r-HuEPO)
Pharmacotherapy.
1990 Mar-Apr.
Abstract
Recombinant human erythropoietin reverses the severe anemia associated with end-stage renal disease. Mean half-life values after a single intravenous bolus dose range from 4-13 hours. Renal clearance is not a significant route of elimination. Dosing schedules in chronic renal failure involve a single intravenous bolus dose administered three times weekly after hemodialysis. Subcutaneous dosing has been approved and may be used in patients without intravenous access. Reticulocyte counts and hematocrit levels exhibit dose-dependent increases; improved hematocrit levels can be sustained with maintenance doses.
Similar articles
-
[Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].Nephrologie. 1992;13(2):87-92. Nephrologie. 1992. PMID: 1608502 French.
-
Erythropoietin response and route of administration.Clin Nephrol. 1994 May;41(5):297-302. Clin Nephrol. 1994. PMID: 8050210 Clinical Trial.
-
Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.Biopharm Drug Dispos. 1996 Dec;17(9):805-15. doi: 10.1002/(SICI)1099-081X(199612)17:9<805::AID-BDD995>3.0.CO;2-H. Biopharm Drug Dispos. 1996. PMID: 8968532
-
Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.Semin Nephrol. 1989 Mar;9(1 Suppl 1):16-21. Semin Nephrol. 1989. PMID: 2648516 Review.
-
Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.Acta Haematol. 1992;87 Suppl 1:16-9. doi: 10.1159/000204783. Acta Haematol. 1992. PMID: 1574961 Review.
Cited by
-
Erythropoiesis stimulating agents: approaches to modulate activity.Biologics. 2013;7:161-74. doi: 10.2147/BTT.S45971. Epub 2013 Jul 3. Biologics. 2013. PMID: 23847411 Free PMC article.
-
A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.J Clin Pharmacol. 2019 Jun;59(6):835-846. doi: 10.1002/jcph.1368. Epub 2019 Jan 7. J Clin Pharmacol. 2019. PMID: 30618050 Free PMC article.
-
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.Pharmacoeconomics. 1993 Jan;3(1):45-82. doi: 10.2165/00019053-199303010-00006. Pharmacoeconomics. 1993. PMID: 10146987 Review.
-
Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.Exp Hematol. 2006 Jun;34(6):697-704. doi: 10.1016/j.exphem.2006.02.011. Exp Hematol. 2006. PMID: 16728273 Free PMC article.
-
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. doi: 10.1073/pnas.0403235101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210944 Free PMC article.